1. Home
  2. APD vs NTRA Comparison

APD vs NTRA Comparison

Compare APD & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Products and Chemicals Inc.

APD

Air Products and Chemicals Inc.

N/A

Current Price

$312.42

Market Cap

68.9B

Sector

Industrials

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

N/A

Current Price

$315.26

Market Cap

56.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
APD
NTRA
Founded
1940
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.9B
56.7B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
APD
NTRA
Price
$312.42
$315.26
Analyst Decision
Buy
Strong Buy
Analyst Count
24
22
Target Price
$342.71
★ $408.69
AVG Volume (30 Days)
1.0M
★ 1.8M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 2.33%
N/A
EPS Growth
N/A
★ 0.65
EPS
★ N/A
N/A
Revenue
★ $12,037,300,000.00
$210,939,000.00
Revenue This Year
$4.28
$29.65
Revenue Next Year
$6.84
$21.05
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$229.11
$181.00
52 Week High
$324.00
$437.41

Technical Indicators

Market Signals
Indicator
APD
NTRA
Relative Strength Index (RSI) 59.49 29.29
Support Level $289.62 $310.50
Resistance Level N/A $334.60
Average True Range (ATR) 6.25 21.23
MACD -0.26 -12.60
Stochastic Oscillator 47.68 7.49

Price Performance

Historical Comparison
APD
NTRA

About APD Air Products and Chemicals Inc.

Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the world's largest supplier of hydrogen and helium. It has a unique portfolio serving customers across industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated roughly $12 billion in revenue in fiscal 2025.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: